RESEARCH ARTICLE

Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis

Yaru Guo1,2‡, Mingna Xu1,2, Yufei Lou1,2, Yan Yuan1,2, Yuling Wu1,2, Longzhen Zhang1, Yong Xin1,2‡*, Fengjuan Zhou2,3‡*

1 Department of Radiation, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China, 2 First Clinical College, Xuzhou Medical University, Xuzhou, China, 3 Department of Radiation, the Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

‡ YX and FZ are co-corresponding authors. YG is first author of this manuscript.
* deep369@163.com (YX); 954811776@qq.com (FZ)

Abstract

Objectives
To compare the survival and complications of neoadjuvant chemoradiation (NCRT) versus neoadjuvant chemotherapy (NCT) for esophageal squamous cell carcinoma (ESCC).

Methods
We conducted a systematic literature search of the PubMed, Web of Science, Cochrane Library, EMBASE, CNKI, Wanfang Data, CBM, and VIP databases from inception to November 2021. Meta-analyses were performed using RevMan (version 5.3) and Stata version 15.0.

Results
A total of 18 studies were included, which involved 3137 patients, The results of the meta-analysis showed that the pathological complete remission rate (odds ratio [OR] = 5.21, 95% confidence interval [CI]: 2.85–9.50, p<0.00001) and complete tumor resection rate (OR = 2.31, 95% CI: 1.57–3.41, p<0.0001) in the NCRT group were significantly better than those in the NCT group. Our meta-analysis results showed that 1-, 3-, and 5-year survival rates (1-year overall survival [OS]: OR = 1.51, 95% CI: 1.11–2.05, p = 0.009; 3-year OS: OR = 1.73, 95% CI: 1.36–2.21, p<0.0001; 5-year OS: OR = 1.61, 95% CI: 1.30–1.99, p<0.00001) in the NCRT group were significantly higher than those in the NCT group. NCRT can lead a significant survival benefit compared with NCT and there was no significant difference between the two neoadjuvant treatments in terms of postoperative complications.
Conclusion

The use of NCRT in the treatment of patients with ESCC patients showed significant advantages in terms of survival and safety relative to the use of NCT.

Introduction

Esophageal cancer (EC) is the eighth most common cancer and sixth leading cause of cancer-related death worldwide [1, 2]. Esophageal squamous cell carcinoma (ESCC) is the main histological cancer type, accounting for approximately 80% of all ECs [3]. ESCC accounts for more than 90% of the total number of ECs in China [4].

Surgery has always been the main treatment for resectable locally advanced EC. However, the overall prognosis for esophagectomy alone is poor [5]. The 5-year overall survival rate after surgery is less than 15%, and the recurrence rate after radical resection of EC ranges 36.8–43.4%, with most recurrences occurring within 2 years after surgery [6–8]. Neoadjuvant treatment, with chemotherapy (NCT) or combined chemoradiotherapy (NCRT), followed by radical surgical resection is now the standard in curatively intended treatment. Neoadjuvant chemoradiation and neoadjuvant chemotherapy have been shown to improve survival in patients with locally advanced EC. According to the CROSS trial from the Netherlands and the NEOCRTEC5010 study from China, NCRT combined surgery can significantly improve the survival of patients with locally advanced EC [9]. The Japanese JCOG9907 study [10] and British OEO2 study [11] confirmed that NCT combined with surgery can bring significant survival benefits over those provided by surgery alone to patients with advanced EC. Neoadjuvant therapy (NCT/NCRT) plus surgery has been used as the standard treatment strategy for patients with locally advanced EC [12]. The Japanese guidelines favor NCT, while NCCN guidelines recommend NCRT as the first-line treatment option for advanced ESCC [13]. The superiority of either NCRT or NCT in the treatment of esophageal cancer remains controversial. Radiotherapy is expected to improve local control, whereas chemotherapy has the potential to eliminate micrometastases [14]. However, there are related studies that reported that neoadjuvant therapy itself is toxic and produces side effects, and that it may also increase the incidence of postoperative complications and mortality, adding radiation to NCT may exacerbate these side effects [15]. Therefore, there is no consensus on which neoadjuvant treatment is the most effective, and there is limited evidence comparing the long-term results of the two induction treatments. Accumulating evidence shows that Esophageal adenocarcinoma (EAC) and ESCC have different natural histories and different cellular origins; therefore, different pathological subtypes of EC have different sensitivities to chemotherapy and radiotherapy [16]. EAC and ESCC have different survival rates and prognoses [17]. ESCC appears to be more sensitive to tumor treatment than EAC, and patients with ESCC gained a greater survival benefit than patients with EAC in the CROSS trial [18].

We believe that these pathological subtypes should be analyzed separately when attempting to determine the best neoadjuvant treatment for esophageal cancer subtypes. Therefore, we collected all the experiments on NCT and NCRT for ESCC, including randomized controlled trials and retrospective experiments. This study aimed to systematically evaluate the survival and complications following NCRT and NCT for ESCC in meta-analysis and to provide evidence to guide the treatment of ESCC.
Materials and methods

This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on December 05, 2021, and was last updated on December 05, 2021 (registration number INPLASY2021120031).

Study inclusion criteria:

i. Diagnosis of ESCC following cytological and histopathological examination in patients without serious cardiac, pulmonary, hepatic, or renal disease.

ii. RCTs or Retrospective experiments comparing NCRT and NCT for treating ESCC.

iii. The experimental design met the requirements and included patients with ESCC and EAC, and a subgroup analysis was performed with ESCC results reported separately.

iv. The primary efficacy outcomes were pathological complete remission rate (pCR); complete (R0) tumor resection rate; 1-, 3-, and 5-year survival rates; toxicity of neoadjuvant treatment (including myelosuppression, gastrointestinal reaction, and esophagitis); and postoperative complications (including anastomotic leak, pulmonary complications, cardiac complications, chyle leak, and perioperative mortality).

Study exclusion criteria:

i. The experimental design included ESCC and EAC were included, but the results for ESCC were not reported separately.

ii. Studies reporting incomplete or inconsistent outcomes.

iii. Duplicate studies, studies reporting animal experiments, case reports, cohort studies, and review articles.

Search strategy and study selection

We identified all studies comparing NCRT and NCT in the treatment of EC in the PubMed, Cochrane Library, Web of Science, Embase, Wanfang Data, Chinese National Knowledge Infrastructure (CNKI), Chinese Biological Medicine (CBM) Database, and VIP Database published before November 2021. We used the following search terms: Esophageal Neoplasms, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Chemotherapy. Two researchers (YG and YL) independently read the titles and abstracts of the identified papers, excluded irrelevant papers according to the inclusion and exclusion criteria. After the initial screening, the researchers read the full text to determine whether to include a study. When opinions were inconsistent, a third party judged whether to include the study.

Data extraction and quality assessment

Two authors (MY and YY) independently extracted the relevant data, including authors; year of publication; country; number of cases; age; stage; NCT regimen; neoadjuvant radiotherapy dose; pCR rate; R0 resection rate; 1-, 3-, and 5-year overall survival (OS); toxicity of neoadjuvant treatment; and postoperative complications. The Cochrane Collaboration’s tool was used to evaluate the quality of randomized studies, and the Newcastle-Ottawa quality assessment scale (NOS) was used for retrospective studies.
Statistical analysis

All statistical analyses were performed using RevMan 5.3 and Stata 15.0. The results are presented as risk ratios (ORs) with 95% confidence intervals (CIs). The heterogeneity between studies were evaluated using Cochran’s Q test and the $I^2$ statistic. A fixed-effects model was used if heterogeneity was not significant ($p > 0.1, I^2 < 50.0$%); otherwise, a random-effects model was applied. The results of the meta-analysis are presented as forest plots. Egger’s test, and sensitivity analysis were used to evaluate publication bias. All p-values are two-sided, and a p-value less than 0.05 was considered statistically significant.

Results

Characteristics of studies

We identified 1326 studies in the initial database search and eliminated 417 duplicate articles and 241 reviews. We excluded 497 irrelevant research studies, 102 studies that studied NCRT combined with surgery vs surgery alone, 21 studies that studied CRT combined with surgery vs surgery alone, 5 studies that met the inclusion criteria that were in progress, 21 studies that included EAC and 4 studies that had inconsistent outcome indicators. Finally, 18 studies were included in the meta-analysis, of which seven [19–25] were randomized trials and eleven [26–36] were retrospective studies. The flow chart of the literature screening process is shown in Fig 1. A total of 2042 patients were included in the NCRT group, and 1095 patients were included in the NCT group. In the included studies, except for three retrospective studies [30, 31, 34] that did not detail the chemotherapy regimens and radiation doses, the chemotherapy regimens were either cisplatin plus 5-fluorouracil or cisplatin plus paclitaxel and the radiation doses were 30–45 Gy in the remaining included studies. The detailed characteristics of each included study are listed in Table 1.

Quality assessment

The quality evaluation results of the seven RCT studies are shown in Fig 2. Three studies assigned random numbers, while none of the remaining studies described any particular randomization method. Only one study reported allocation concealment. Three studies that included patients who signed an informed consent did not follow a blinding method, and the remaining four studies did not have sufficient information to determine whether a blinding method was followed. All included studies presented complete data for analysis and no selective reporting or other biases were identified. The Newcastle–Ottawa scale was used to assess the quality of the eleven retrospective studies, and all scores were greater than 6 points; the evaluation results are shown in Table 1. This indicates that all the studies were of relatively high quality.

pCR

Eleven included studies reported pCR [20, 22, 23, 26, 28–30, 32, 33, 35, 36]. There was heterogeneity between studies ($p = 0.008, I^2 = 58$%); therefore, a random-effects model was used for the meta-analysis. Meta-analysis showed that the pCR rate of the NCRT group was significantly higher than that of the NCT group (OR = 5.21, 95% CI:2.85–9.50, $p < 0.00001$) (Fig 3).

R0 resection

Ten included studies reported R0 resection [20, 22, 23, 25, 26, 28, 29, 32, 35, 36]. There was no significant heterogeneity between studies ($p = 0.33, I^2 = 12$%); therefore, the fixed-effects model was used for the meta-analysis. Meta-analysis showed that R0 resection in the NCRT
group was significantly higher than that in the NCT group (OR = 2.31, 95% CI:1.57–3.41, \( p < 0.0001 \)) (Fig 4).

One-, three-, and five-year survival rates
Nine studies reported 1-year survival rates (\( p = 0.78, I^2 = 0\% \)) and 3-year survival rates (\( p = 0.20, I^2 = 28\% \)) [20–22, 25, 26, 28, 33, 35, 36], and the fixed-effects model was selected
because no significant heterogeneity was found. Ten included articles reported 5-year survival rates [20–22, 24, 26, 29, 31, 32, 34, 36], and the fixed-effects model was selected because significant heterogeneity was found (p = 0.10, I² = 39%). The results of the meta-analysis showed that the 1-year (OR = 1.51, 95% CI: 1.11–2.05, p = 0.009), 3-year (OR = 1.73, 95% CI: 1.36–2.21, p < 0.0001), and 5-year survival rates (OR = 1.61, 95% CI: <0.00001) were higher in the NCRT group than in the NCT group. All differences were statistically significant (Fig 5).

Postoperative complications

Ten studies reported perioperative mortality [22, 23, 25, 26, 28, 29, 32–35], ten studies reported anastomotic leak [20–22, 25, 26, 28, 29, 32, 33, 35], eight studies reported pulmonary complications [21, 25, 26, 28, 29, 32, 33, 35], five studies reported cardiac complications [21, 26, 28, 29, 35], four studies reported chyle leak [21, 22, 26, 35], four studies reported stricture [20, 22, 28, 35], three studies reported postoperative vocal cord paralysis [21, 26, 35], three studies reported postoperative bleeding [20, 22, 26], and two studies reported postoperative infection [26, 35]. No heterogeneity was found for any complication; therefore, a fixed-effects model was used for analysis. Table 2 shows the results of the meta-analysis of all postoperative complications. According to the results, the perioperative mortality rate of the NCRT group was similar to that of the NCT group (OR = 0.97, 95% CI: 0.55–1.72). The rates of anastomotic leak, pulmonary complications, cardiac complications, chyle leak, stricture, postoperative vocal cord paralysis, and infection in the NCRT group were higher than those in the CRT group, and the rate of bleeding in the NCRT group was lower than that in the CRT group;

### Table 1. The characteristics of studies included.

| Author       | Year | Country | Study design | n(nCRT/nCT) | Age/years | Stage | nCRT | nCT | NOS |
|--------------|------|---------|--------------|-------------|-----------|-------|------|-----|-----|
| Qi WX [31]   | 2021 | China   | retrospective | 275/55 | 63±8.8 | 65±1.3 | II-IV | -   | 6   |
| Zhang GC [29]| 2021 | China   | retrospective | 90/90 | 18–75 | 18–75 | I-IVA | NDP/DDP+PTX/5Fu+32.4–50.0Gy | NDP/DDP+PTX/5-Fu | 6   |
| Wu YY [19]   | 2020 | China   | RCT          | 40/40 | 58.4±7.5 | 59.2±8.3 | III-IV | PTX+DDP+41.4Gy | PTX+DDP | -   |
| Fu LD [21]   | 2019 | China   | RCT          | 60/60 | 57.6±9.5 | 56.5±9.8 | III-IV | PTX+DDP+40Gy | PTX+DDP | -   |
| Miller [34]  | 2018 | America | retrospective | 827/75 | 60.4±9.4 | 62.8±9.8 | I-IV | -   | -   |
| Nakashima [32]| 2018 | Japan   | retrospective | 60/60 | 63.6 | 64.2 | II-IV | DDP+5-Fu+27-50Gy | DDP+5-Fu | 7   |
| Shi JR [27]  | 2018 | China   | retrospective | 46/46 | 55.05±15.28 | 56.05±15.86 | III-IV | DDP+5-Fu+55-66Gy | DDP+5-Fu | 8   |
| von Döbeln [23]| 2018 | Sweden  | RCT        | 25/25 | <70 | <70 | III-IV | DDP+5-Fu+40Gy | DDP+5-Fu | -   |
| Hao DX [35]  | 2017 | China   | retrospective | 53/58 | 30–74 | 30–71 | II-III | DDP+5-Fu+40Gy | DDP+5-Fu | 7   |
| Tiesi [30]   | 2017 | America | retrospective | 25/30 | 63±0.8 | 65±1.3 | II-IV | -   | -   |
| Li X [28]    | 2017 | China   | retrospective | 72/105 | 60(30–80) | 60(30–80) | III-IV | DDP+5-Fu+36-40Gy | DDP+5-Fu | 8   |
| Zheng H [26] | 2017 | China   | retrospective | 59/97 | 60(41–79) | 60(41–79) | III-IV | PTX+DDP+40Gy | PTX+DDP | 8   |
| Kleebro [36] | 2016 | Sweden  | retrospective | 79/19 | 63 (20–80) | 63 (35–79) | I-III | DDP/ADM+5-Fu+40Gy | DDP/ADM+5-Fu | 7   |
| Skoczylas [24]| 2014 | Poland  | RCT         | 30/23 | -    | -    | II-III | DDP+5-Fu+30Gy | DDP+5-Fu | -   |
| Lu J [20]    | 2009 | China   | RCT         | 119/120 | 40–70 | 40–70 | II-IV | PTX+DDP+40Gy | PTX+DDP | -   |
| Cao XF [22]  | 2007 | China   | RCT         | 118/119 | -    | -    | II-IV | MMC+DDP+5-Fu+40Gy | MMC+DDP+5-Fu | -   |
| Nakano [33]  | 2001 | Japan   | retrospective | 17/23 | 63.4±5.6 | 63.7±8.1 | II-IV | DDP+5-Fu+40Gy | DDP+5-Fu | 8   |
| Nygaard [25] | 1992 | Norway  | RCT         | 34/41 | 60.1(50–74) | 62.9(44–77) | I-III | BLM+DDP+35Gy | BLM+DDP | -   |
however, The difference is not statistically significant (Fig 6). We considered no difference in complication rates between the two groups.

**Evaluation of sensitivity and publication bias**

To ensure the accuracy and stability of the research, we conducted a sensitivity analysis by omitting each study to assess its effect on the overall results. Each study was not out of the
estimated ranges by visual inspection and had no significant effect on the results (Fig 7), indicating that the strong rationality and reliability of the results of our meta-analysis. We analyzed the symmetry of the funnel plot using Egger’s regression test (S1 Fig), and the results showed that none of the articles had publication bias (Table 3), and all P-values > 0.05.

**Discussion**

The incidence of EC is increasing, and EC is the the fourth most cause of cancer-related death in China [37]. In recent years, combined NCT and NCRT have become the standard treatment options for EC. However, the evidence to define the most beneficial neoadjuvant treatment for EC is insufficient [38]; consequently, which neoadjuvant regimen is most effective for patients with EC has remained a controversial topic. Patients with ESCC and ESAC all showed higher tumor responses to NCT and NCRT, but patients with ESCC showed higher sensitivity and significantly better survival after treatment with NCRT; in patients with ESAC, tumor response did not translate to improved survival. In addition to efficacy, NCT and NCRT treatment

---

**Fig 3.** Forest plot for pCR of NCRT group and NCT group.

https://doi.org/10.1371/journal.pone.0271242.g003

**Fig 4.** Forest plot for R0 resection of NCRT group and NCT group.

https://doi.org/10.1371/journal.pone.0271242.g004
Fig 5. Forest plot for one-year (A), three-year (B), and five-year (C) survival rates of NCRT group and NCT group.

https://doi.org/10.1371/journal.pone.0271242.g005
options also need to consider the risk of toxicity and complications [23, 9, 39]. To ensure the completeness and reliability of the results, we included all RCTs and retrospective analyses of ESCC treatment published before November 2021.

The pCR is defined as fibrosis with or without inflammation extending through different layers of the esophageal wall, but with no viable residual tumor cells. Brücher et al. investigated the association between histopathological regression and survival in 311 patients with ESCC treated with NCRT/CRT. The results revealed that the histopathologic response classification according to the percentage of residual tumor cells was an independent prognostic factor \( p < 0.001 \). Non-responders had higher postoperative pulmonary morbidity, a higher 30-day mortality rate, and a lower survival rate compared to those of histopathologic responders \( p < 0.001 \). pCR was an independent significant predictor for EC, and patients who achieved pCR had better progression free survival (PFS) and OS than those without pCR [40]. The results of this meta-analysis showed that NCRT can result in better pCR rates in patients with ESCC than those achieved with CRT (OR = 5.21, 95% CI: 2.85–9.50, \( p < 0.00001 \)), which means that it can provide better survival benefits.

Complete (R0) tumor resection was defined as complete tumor excision with all margins histologically free of tumor. R0 resection is the most important predictor of OS in patients with EC [11]. Both NCRT and NCT can increase the R0 resection rate of EC, and the R0 resection rate was higher in the NCRT group than in the surgery alone group in the CROSS study (92% vs. 65%). In the JCOG9907 study, R0 resection of the NCT group and surgery alone group was 85.4% and 65%, respectively. The results of our meta-analysis show that the R0 resection rate was higher in the NCRT group than in the NCT group (OR = 2.31, 95% CI: 1.57–3.41, \( p < 0.0001 \)).

Neoadjuvant treatments can improve the survival rate of patients with ESCC. NCRT and NCT have obvious advantages compared to surgery alone; however, it is still unclear which of the two can provide greater survival benefits to patients with ESCC. In the literature that we included, except for 1-year OS of Daxuan Hao’s study and 5-year OS of Nakashima and Miller’s study were higher in the NCT group than in the NCRT group. The 1-year, 3-year, and 5-year OS rates in the NCRT group were higher than those in the NCT group in the remaining studies. Our meta-analysis showed that the 1-, 3-, and 5-year survival rates in the NCRT group were significantly better than those in the NCT group, The results were statistically significant.

### Table 2. Summary of the results of meta-analysis.

| Outcomes and complications | Included study | Events | Total of EXP | Events | Total of CON | Heterogeneity | Meta-analysis model | Result of meta-analysis |
|---------------------------|----------------|--------|--------------|--------|--------------|---------------|---------------------|------------------------|
| pCR                       | 11             | 188    | 717          | 45     | 746          | 0.008         | random-effects      | 5.21(2.85–9.50) <0.00001 |
| 0 resection               | 10             | 660    | 722          | 643    | 745          | 0.33          | fixed-effects       | 2.31(1.57–3.41) <0.0001  |
| 1-year OS                 | 9              | 517    | 618          | 509    | 651          | 0.78          | fixed-effects       | 1.51(1.11–2.05) 0.009    |
| 3-year OS                 | 9              | 373    | 597          | 324    | 645          | 0.20          | fixed-effects       | 1.73(1.36–2.21) <0.0001  |
| 5-year OS                 | 10             | 746    | 1664         | 274    | 705          | 0.10          | fixed-effects       | 1.61(1.30–1.99) <0.00001  |
| Perioperative mortality   | 10             | 59     | 1355         | 23     | 693          | 0.85          | fixed-effects       | 0.97(0.55–1.72) 0.92     |
| Anastomotic leak          | 10             | 62     | 682          | 60     | 773          | 0.11          | fixed-effects       | 1.23(0.84–1.81) 0.28     |
| Pulmonary complications   | 8              | 60     | 445          | 58     | 534          | 0.30          | fixed-effects       | 1.31(0.88–2.13) 0.18     |
| Cardiac complications     | 5              | 11     | 334          | 9      | 410          | 0.81          | fixed-effects       | 1.44(0.60–3.47) 0.42     |
| Stricture                 | 4              | 6      | 290          | 6      | 334          | 0.69          | fixed-effects       | 1.100(0.36–3.31) 0.87    |
| Chyle leak                | 4              | 9      | 362          | 6      | 402          | 0.59          | fixed-effects       | 1.66(0.62–4.48) 0.31     |
| Postoperative vocal cord  | 3              | 8      | 172          | 6      | 215          | 0.54          | fixed-effects       | 1.46(0.53–4.02) 0.47     |
| Paralysis                 | 3              | 2      | 296          | 3      | 336          | 0.95          | fixed-effects       | 0.84(0.16–4.38) 0.83     |
| Infection                 | 2              | 3      | 112          | 2      | 155          | 0.37          | fixed-effects       | 1.79(0.34–9.58) 0.49     |

https://doi.org/10.1371/journal.pone.0271242.t002
A meta-analysis of NCRT vs CRT for esophageal squamous cell cancer

![Forest plot for postoperative complications of NCRT group and NCT group.](https://doi.org/10.1371/journal.pone.0271242.g006)

**Fig 6.** Forest plot for postoperative complications of NCRT group and NCT group.

https://doi.org/10.1371/journal.pone.0271242.g006
Fig 7. Sensitivity analysis of pCR (A), R0 resection (B), 1-year survival rates (C), 3-year survival rates (D) and 5-year survival rates (E) of NCRT group and NCT group.

https://doi.org/10.1371/journal.pone.0271242.g007
NCT plus radiotherapy may increase treatment-related toxicity and postoperative complication rates [41]. In our meta-analysis, we also analyzed complications after neoadjuvant treatment, and the results showed that there was no significant difference in the incidence of myelosuppression, gastrointestinal reaction, or esophagitis between the two groups (S2 Fig). The results of our meta-analysis showed that there was no significant difference between the two neoadjuvant treatments in terms of postoperative complications and perioperative mortality. There is an ongoing trial CMISG1701 [42], which is a multicenter prospective randomized phase III clinical trial, comparing NCRT combined with minimally invasive surgery to NCT combined with minimally invasive surgery in patients with locally advanced resectable ESCC (cT3-4aN0-1M0) in China. Progress in minimally invasive surgery is bound to reduce postoperative complication rates. We look forward to the results of this study that may provide greater survival benefits to patients with ESCC.

In the treatment of ESCC, many scholars have realized that whether patients benefit from neoadjuvant therapy may be related to differences in gene expression, and people with certain molecular markers may be sensitive to neoadjuvant therapy [43]. Schneider et al. showed that the expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), excision repair cross complementing factor 1 (ERCC1), glutathione S-transferase Pi (GST-Pi), epidermal growth factor receptor (EGFR), and HER2 genes in ESCC resection specimens dropped significantly after neoadjuvant therapy [44]. However, there is no conclusive evidence that certain genes can guide NAT. Four studies of our included articles compared the complete clinical remission (cCR) rate after two neoadjuvant treatment. The results showed that the cCR of the NCRT group was higher than that of the NCT group (OR = 4.00, 95% CI: 2.41–6.64, p<0.00001) (S3 Fig). Two European trials, ESOSTRATE [45] and SANO [46], tested the hypothesis that patients with cCR after neoadjuvant therapy do not require esophagectomy. Patients receiving NCRT will be randomly divided into surgery and watchful waiting groups, and the main study parameter is overall survival. We look forward to the results of these two studies, which can show that patients who achieve complete remission after neoadjuvant treatment without surgery can achieve greater survival benefits and improved quality of life. Currently, immune-based treatment methods have shown great potential in the treatment of EC, and the combined treatment with NCT or NCRT regimens is more effective. CheckMate 577 was aimed at evaluating a checkpoint inhibitor as an adjuvant therapy in patients with resected EC or gastroesophageal junction cancer who had received NCRT. The results showed that the DFS of patients receiving adjuvant nivolumab was significantly greater than that of patients receiving placebo [47]. In the era of precision medicine, the treatment of EC should depend on the molecular biological characteristics of tumors and follow the principles of evidence-based medicine to formulate individualized treatment plans in a targeted manner, which will be the main direction of adjuvant radiotherapy and chemotherapy for ESCC in the future.

Table 3. Publication bias results of the included studies.

| Evaluation Items | t      | 95%CI    | P       |
|------------------|--------|----------|---------|
| pCR              | 1.34   | -1.419   | 5.547   | 0.213   |
| R0 reaction      | 0.79   | -1.401   | 2.868   | 0.451   |
| One-year OS      | 0.30   | -2.769   | 3.58    | 0.771   |
| Three-year OS    | 0.30   | -2.587   | 3.326   | 0.776   |
| Five-year OS     | 0.60   | -2.348   | 3.985   | 0.568   |

https://doi.org/10.1371/journal.pone.0271242.t003
Limitations

Our meta-analysis had some limitations. First, there were three studies where we could not obtain information on the neoadjuvant therapy. Second, because randomized trials directly comparing NCRT and NCT used in the treatment of EACC are limited, we also included prospective studies; as far as we know, there are three ongoing randomized controlled trials comparing NCRT vs NCT for patients with ESCC. The aim of JCOG1109 [48] which comes from Japan, was to confirm that docetaxel, cisplatin, and 5-fluorouracil are better than cisplatin plus 5-fluorouracil, and cisplatin plus 5-fluorouracil combined with chemotherapy and radiotherapy is better than cisplatin plus 5-fluorouracil as a preoperative treatment for ESCC. CMISG1701 [43] and HCHTOG1903 [49] are from China. HCHTOG1903 aimed to compare the OS rates of patients with locally advanced ESCC who received NCT and standard CROSS. We look forward to the results of these large randomized controlled clinical studies, which can guide us to better treat ESCC.

Conclusion

In conclusion, compared with NCT in the treatment of ESCC, NCRT can significantly increased the rates of pCR and R0 resection, and can more significantly improve the long-term survival of patients with ESCC without significantly increasing postoperative complications.

Supporting information

S1 Fig. Egger’s tests for publication bias of pCR (A), R0 resection (B), 1-year survival rates (C), 3-year survival rates (D) and 5-year survival rates (E) of NCRT group and NCT group. (TIF)

S2 Fig. Forest plot for myelosuppression (A), gastrointestinal reaction (B), esophagitis (C) between NCRT group and NCT group. (TIF)

S3 Fig. Forest plot for cCR of NCRT group and NCT group. (TIF)

S1 Checklist. PRISMA checklist. (DOC)

S2 Checklist. PRISMA-P checklist. (DOC)

Author Contributions

Data curation: Yaru Guo, Mingna Xu, Yufei Lou, Yan Yuan.

Formal analysis: Yaru Guo, Yufei Lou, Fengjuan Zhou.

Funding acquisition: Yaru Guo, Longzhen Zhang.

Investigation: Yan Yuan, Yuling Wu.

Project administration: Yaru Guo.

Resources: Yaru Guo.

Software: Yaru Guo, Yufei Lou.
Supervision: Yong Xin, Fengjuan Zhou.

Writing – original draft: Yaru Guo.

References

1. Zhang X, Peng L, Luo Y, Zhang S, Pu Y, Chen Y, et al. Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis. Nat Commun (2021) 12(1):5291. https://doi.org/10.1038/s41467-021-25539-x PMID: 34489433.

2. He Z, Yi J, Liu X, Chen J, Han S, Jin L, et al. MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial-mesenchymal transition by targeting Oki-5 in esophageal squamous cell carcinoma. Mol Cancer (2016) 15(1):51. https://doi.org/10.1186/s12943-016-0533-3 PMID: 27358073.

3. Liang Y, Chen X, Wu Y, Li J, Zhang S, Wang K, et al. LncRNA CASC9 promotes esophageal squamous cell carcinoma metastasis through upregulating LAMC2 expression by interacting with the CREB-binding protein. Cell Death Differ (2018) 25(11):1980–95. https://doi.org/10.1038/s41418-018-0088-9 PMID: 29511340.

4. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin (2015) 65(2):87–108. https://doi.org/10.3322/caac.21262 PMID: 25651787.

5. Shah MA, Kennedy EB, Catenacci DV, Deighton DC, Goodman KA, Malhotra NK, et al. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. J Clin Oncol (2020) 38(23):2677–94. https://doi.org/10.1200/JCO.20.00866 PMID: 32568633.

6. Honing J, Smit JK, Muijs CT, Burgerhof J, de Groot JW, Paardekooper G, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol (2014) 25(3):638–43. https://doi.org/10.1093/annonc/mdt589 PMID: 24492674.

7. Fujishiro T, Shuto K, Hayano K, Satoh A, Kono T, Ohira G, et al. Preoperative hepatic CT perfusion as an early predictor for the recurrence of esophageal squamous cell carcinoma: initial clinical results. Oncol Rep (2014) 31(3):1083–8. https://doi.org/10.3892/or.2014.2992 PMID: 24452736.

8. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol (2008) 26(7):1086–92. https://doi.org/10.1200/JCO.2007.12.9593 PMID: 18309943.

9. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge HM, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med (2012) 366(22):2074–84. https://doi.org/10.1056/NEJMoa1112088 PMID: 22646630.

10. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol (2012) 19(1):68–74. https://doi.org/10.1245/s10434-011-2049-9 PMID: 21879261.

11. Allum WH, Stenning SP, Baneewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol (2009) 27(30):5062–7. https://doi.org/10.1200/JCO.2009.22.2083 PMID: 19770374.

12. Chen MQ, Chen C, Lu HJ, Xu BH. The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma. J Thorac Dis (2015) 7(10):1749–55. https://doi.org/10.3978/j.issn.2072-1439.2015.10.23 PMID: 26623097.

13. Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2019) 17(7):855–83. https://doi.org/10.6040/jncn.2019.0033 PMID: 31319389.

14. Ishikawa T, Yasuda T, Okayama T, Dohi O, Yoshida N, Kamada K, et al. Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study. Cancer Sci (2019) 110(12):3754–60. https://doi.org/10.1111/cas.14218 PMID: 31647614.

15. Sanford NN, Catalano PJ, Enzinger PC, King BL, Bueno R, Martin NE, et al. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer. Dis Esophagus (2017) 30(7):1–8. https://doi.org/10.1093/dote/dox025 PMID: 28475728.

16. Pucher PH, Rahman SA, Walker RC, Grace BL, Bateman A, Iveson T, et al. Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis. Ejsco-Eur J Surg Onc (2020) 46(12):2248–56. https://doi.org/10.1016/j.ejso.2020.06.036 PMID: 32694054.
17. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. *Ann Surg* (2001) 234(3): 360–7. 368–9. https://doi.org/10.1097/00000658-200109000-00010 PMID: 11524589.

18. Swisher SG, Hofstetter W, Komaki R, Correa AM, Erasmus J, Lee JH, et al. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. *Ann Thorac Surg* (2010) 90(3):892–8. https://doi.org/10.1016/j.athoracsur.2010.04.061 PMID: 20732514

19. Yingying Wu. Effect of neoadjuvant concurrent chemoradiotherapy on downstaging rate in patients with locally advanced esophageal squamous cell carcinoma. Contemporary Med 2020; 26: 17–19

20. Jin Lu, Xifeng Cao and Bin Zhu, et al. Surgery combined with preoperative chemoradiotherapy in the treatment of esophageal squamous cell carcinoma. Chinese Journal of Experimental Surgery 2009: 1378–1380

21. Lida Fu, Lizhi Jian and Shang Wu. The efficacy of neoadjuvant chemotherapy and concurrent neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma. Liaoning Medical Journal 2019; 33: 18–20.

22. Xifeng Cao, Shan Wang and Bichao Wu, et al. Effects of neoadjuvant chemoradiotherapy on pathological staging and prognosis of advanced esophageal squamous cell carcinoma. World Chinese Journal of Digestion 2007; 15: 2413–2417.

23. Von Döbeln GA, Klevebro F, Jacobsen AB, Johannessen HO, Nielsen NH, Johnsen G, et al. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastro-esophageal junction: Long-term results of a randomized clinical trial. *Dis Esophagus* (2019) 32(2). https://doi.org/10.1093/dote/doy078 PMID: 30137281

24. Skoczylas T, Wallner G, Dabrowski A, Laudanski J, Szawloski A, Lampé P. The impact of neoadjuvant chemotherapy and chemoradiotherapy on long-term outcome in squamous cell carcinoma of the thoracic esophagus: An analysis of the prospective randomized multicenter trial. *J Am Coll Surg* (2014) 219(4):e46. https://doi.org/10.1016/j.jamcollsurg.2014.07.505

25. Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. *World J Surg* (1992) 16(6):1104–9, 1110. https://doi.org/10.1007/BF02067069 PMID: 1455880.

26. Hao Zheng, Hao Wang and Han Tang, et al. Efficacy analysis of neoadjuvant concurrent chemoradiotherapy and neoadjuvant chemotherapy in the treatment of locally advanced esophageal squamous cell carcinoma. Chinese Journal of Digestive Surgery 2017; 16: 464–468.

27. Junrong Shi. Comparison of the effect of neoadjuvant concurrent chemoradiotherapy and neoadjuvant chemotherapy in the treatment of locally advanced esophageal squamous cell carcinoma. Chinese and Foreign Med Research 2016; 16: 31–33.

28. Xue Li, Zhanghua Hao and Yuanyuan Yang, et al. Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma. Chinese Journal of Radiation Oncology 2017; 26: 274–278.

29. Zhang G, Zhang C, Sun N, Xue L, Yang Z, Fang L, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China. *J Cancer Res Clin Oncol* (2021). https://doi.org/10.1007/s00432-021-03659-7 PMID: 34013382.

30. Tiesi G, Park W, Gunder M, Rubio G, Berger M, Ardalain B, et al. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer. *J Surg Res* (2017) 216:65–72. https://doi.org/10.1016/j.jss.2017.03.022 PMID: 28807215

31. Qi W, Chen C, Zhao S, Chen J. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of locally advanced esophageal cancer: a population-based analysis. *Int J Clin Oncol* (2021). https://doi.org/10.1007/s10147-021-02056-x PMID: 34731352

32. Nakashima Y, Saeki H, Hu Q, Tsuda Y, Hisamatsu Y, Ando K, et al. Neoadjuvant chemotherapy versus chemoradiotherapy for patients with esophageal squamous cell carcinoma. *Anticancer Res* (2018) 38 (12):6809–14. https://doi.org/10.21873/anticancer.13053 PMID: 30504394

33. Nakano S, Baba M, Natsugoe S, Kusano C, Shimada M, Fukumoto T, et al. The role of neoadjuvant radiochemotherapy using low-dose fraction cisplatin and 5-fluorouracil in patients with carcinoma of the esophagus. *The Japanese Journal of Thoracic and Cardiovascular Surgery* (2001) 49(1). https://doi.org/10.1007/BF02913117 PMID: 11233236

34. Miller JA, Groman A, Yendamuri S, Hennon M. Radiation With Neoadjuvant Chemotherapy Does Not Improve Outcomes in Esophageal Squamous Cell Cancer. *J Surg Res* (2019) 236:259–65. https://doi.org/10.1016/j.jss.2018.11.052 PMID: 30694764.
35. Hao D, Li X, Yang Y, Zhang Y, Wu X, Chen Y, et al. Neoadjuvant chemoradiotherapy versus chemotherapy and surgery for patients with locally advanced esophageal squamous cell carcinoma. *J Clin Oncol* (2017) 34(4).

36. Klevebro F, Lindblad M, Johansson J, Lundell L, Nilsson M. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry. *Br J Surg* (2016) 103(13):1864–73. [https://doi.org/10.1002/bjs.10304](https://doi.org/10.1002/bjs.10304) PMID: 27689845.

37. Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, et al. Cancer incidence and mortality in China, 2013. *Cancer Lett* (2017) 401:63–71. [https://doi.org/10.1016/j.canlet.2017.04.024](https://doi.org/10.1016/j.canlet.2017.04.024) PMID: 28476483.

38. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrnschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. *J Clin Oncol* (2009) 27(6):851–6. [https://doi.org/10.1200/JCO.2008.17.0506](https://doi.org/10.1200/JCO.2008.17.0506) PMID: 19139439.

39. Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. *Eur J Cancer* (2011) 47(3):354–60. [https://doi.org/10.1016/j.ejca.2010.09.009](https://doi.org/10.1016/j.ejca.2010.09.009) PMID: 21084184.

40. Li C, Lin JW, Yeh HL, Chuang CY, Chen CC. Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism. *Sci Rep* (2021) 11(1):11626. [https://doi.org/10.1038/s41598-021-90753-y](https://doi.org/10.1038/s41598-021-90753-y) PMID: 34078965.

41. Jing S, Qin J, Liu Q, Zhai C, Wu Y, Cheng Y, et al. Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis. *Future Oncol* (2019) 15(20):2413–22. [https://doi.org/10.2217/fon-2019-0024](https://doi.org/10.2217/fon-2019-0024) PMID: 31269806.

42. Sunada F, Itabashi M, Ohkura H, Okumura T. p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy. *World J Gastroenterol* (2005) 11(36):5696–700. [https://doi.org/10.3748/wjg.v11.i36.5696](https://doi.org/10.3748/wjg.v11.i36.5696) PMID: 16237768.

43. Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. *J Am Coll Surg* (2005) 200(3):336–44. [https://doi.org/10.1016/j.jamcollsurg.2004.10.035](https://doi.org/10.1016/j.jamcollsurg.2004.10.035) PMID: 15737843.

44. Bedenne L, Mariette C. Comparison of systematic surgery versus surveillance and rescue surgery in operable oesophageal cancer with a complete clinical response to radiochemotherapy (Esostrate). Available at: ClinicalTrials.gov Identifier: NCT02551458 (2015).

45. Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. *J Am Coll Surg* (2005) 200(3):336–44. [https://doi.org/10.1016/j.jamcollsurg.2004.10.035](https://doi.org/10.1016/j.jamcollsurg.2004.10.035) PMID: 15737843.

46. Noordman BJ, Wijnhoven B, Lagarde SM, Boonstra JJ, Coene P, Dekker J, et al. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. *Bmc Cancer* (2018) 18(1):142. [https://doi.org/10.1186/s12885-018-4034-1](https://doi.org/10.1186/s12885-018-4034-1) PMID: 29409469.

47. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. *N Engl J Med* (2021) 384(13):1191–203. [https://doi.org/10.1056/NEJMoa2032125](https://doi.org/10.1056/NEJMoa2032125) PMID: 33789008.

48. Nakamura K, Kato K, Iyagi H, Ito Y, Mizusawa J, Ando N, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NEXt study). *Jpn J Clin Oncol* (2013) 43(7):752–5. [https://doi.org/10.1093/jjco/hyt061](https://doi.org/10.1093/jjco/hyt061) PMID: 23625063.

49. Sun H, Xing W, Liu X, Zheng Y, Yang S, Wang Z, et al. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903). *Bmc Cancer* (2020) 20(5).